--- a
+++ b/clusters/9knumclustersv2/clust_1026.txt
@@ -0,0 +1,81 @@
+Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the Investigator, may interfere with oral drug absorption
+Unable to swallow tablets, patients with malabsorption syndrome, or any other GI disease or GI function that could interfere with absorption of study treatment
+Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastro intestinal function or GI disease
+Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of AG-, including any unresolved nausea, vomiting, or diarrhea that is National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >.
+Active gastrointestinal (GI) conditions and uncontrolled irritable bowel disease or pre-existing GI disorders that may interfere with proper absorption of the study drug
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of venetoclax
+Has malabsorption due to prior gastrointestinal (GI) surgery or GI disease
+GI condition that might limit absorption of oral agents
+Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption.
+Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow
+Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption (e.g. malabsorption syndrome, history of biliary tract disease), including refractory nausea or vomiting, or chronic GI disease which may affect absorption or tolerance to oral medications
+Impairment of gastro intestinal (GI) function or GI disease.
+Patients who are unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatment
+Patients unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatment
+Patient is unable to swallow oral medications or has impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption (including, but not limited to active inflammatory bowel disease, malabsorption syndrome); concomitant therapy with antacids and anti-emetics is permissible
+Major surgery to the upper GI tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption
+Patients unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatment
+Impairment of GI function or GI disease that may significantly alter the absorption of INC
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
+Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow up to five ceritinib capsules daily
+Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LCL as per physicians opinion
+Patients with known significant impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of quizartinib.
+Impairment of GI function
+Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs
+Patient must not have prior gastrointestinal (GI) surgery or GI disease that might interfere with the absorption of TRC
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) grade > 
+Must be able to swallow capsules and have no evidence of gastrointestinal (GI) tract abnormality that would alter the absorption of oral medications
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the swallowing absorption of panobinostat and MLN
+Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of sorafenib
+Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of midostaurin; patients with gastric bypass surgery are excluded
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of GS-, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) Grade > 
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >.
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of GS-, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) Grade > 
+Patients with known severe impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of sorafenib
+Any gastrointestinal (GI) disorder or liver disease
+Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract.
+Impairment of gastrointestinal (GI) function
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
+Impairment of GI function or GI disease that may significantly alter capecitabine drug absorption
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of ceritinib or LEE
+Presence of GI fistula
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
+Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LCL
+Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of midostaurin
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PANOBINOSTAT or RUXOLITINIB
+History of gastrointestinal (GI) surgery within the past  days; if >  days since GI surgery, must have confirmation of complete healing before initiating treatment with study drug
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
+Malabsorption due to prior gastrointestinal (GI) surgery, GI disease
+Subjects are willing to undergo or must have had an endoscopy of the upper and/or lower GI tract and biopsy to confirm GI GVHD.
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
+Major gastrointestinal (GI) disease as defined but not limited to the following: history of inflammatory bowel disease or other illness resulting in chronic diarrhea, known achlorhydria or history of GI surgery that could reduce the acidity of the stomach, acute pancreatitis or cholecystitis within  months prior to Baseline, or GI disease that may interfere with the absorption of orally-administered drugs.
+Impairment of GI function or GI disease that could interfere with the absorption of selinexor, including obstructed GI tract and uncontrolled vomiting or diarrhea.
+Impairment of gastrointestinal (GI) function or GI disease that might significantly alter the absorption of study drug
+Impaired GI function or GI disease
+Patients with gastrointestinal (GI) absorptive problems making it unlikely to absorb study medication or more likely to experience GI toxicities
+RECURRENT/ PROGRESSIVE DIPG (STRATUM ): Patients have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat; for example severe inflammatory bowel disease
+NON-PROGRESSED DIPG (STRATUM ): Patients have impairment of GI function or GI disease that may significantly alter the absorption of panobinostat; for example severe inflammatory bowel disease
+Impairment of GI function or GI disease that may significantly alter the absorption of ceritinib
+Patient must not have prior gastrointestinal (GI) surgery or GI disease that might interfere with the absorption of terameprocol
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LBH
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >
+Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug.
+Impairment of GI function or GI disease that may significantly alter the absorption of panobinostat.
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral WNT/LGX
+Impaired GI function or GI disease that may interfere with absorption of AZD or patients unable to take oral medication
+Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption
+Impairment of GI function or GI disease that could interfere with the absorption of AEB or everolimus.
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
+Impairment of gastro-intestinal (GI) function or GI disease that may significantly alter the absorption of LEE such as patients with a history of GI surgery which may result in intestinal blind loops and patients with clinically significant gastroparesis, unresolved nausea, vomiting, or diarrhea of CTCAE grade > 
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat
+Impairment of GI function or GI disease that may significantly alter the absorption of LBH
+Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption) (e.g. malabsorption syndrome, history of biliary tract disease)
+Impaired gastrointestinal function (GI) or GI disease that may significantly alter the absorption of oral medications
+History of clinically-significant gastrointestinal (GI) disease; GI perforation within  year; GI bleeding or acute pancreatitis within  months; or diverticulitis within  weeks of first study drug administration
+History of malabsorption or other gastrointestinal (GI) disease that may significantly alter the absorption of LAM-A
+History of GI ulcers, chronic GERD, or GI bleeding in the past  years
+Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >
+Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption